Active, not recruitingPhase 3NCT05164341
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Studying Acquired partial lipodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amryt Pharma
- Intervention
- metreleptin(drug)
- Enrollment
- 69 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- University of Alabama, Birmingham, Alabama, United States
- UC Davis, Sacramento, California, United States
- Flourish Boca Raton, Boca Raton, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University of Missouri, Columbia, Missouri, United States
- Amryt Research Site, Endocrinology Research Associates Inc, Columbus, Ohio, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- UZ Leuven, Leuven, Belgium
- Universitário Walter Cantídio, Fortaleza, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05164341 on ClinicalTrials.govOther trials for Acquired partial lipodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07516496Metabolic Phenotyping in vEDSCambridge University Hospitals NHS Foundation Trust
- RECRUITINGPHASE4NCT06484868Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyAmryt Pharma
- RECRUITINGNCT05996536Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- RECRUITINGPHASE2NCT05470504Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin ResistanceNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- RECRUITINGNANCT03900286Low Energy Diet and Familial Partial LipodystrophyCambridge University Hospitals NHS Foundation Trust
- ACTIVE NOT RECRUITINGPHASE2NCT02262806Compassionate Use of Metreleptin in Previously Treated People With Partial LipodystrophyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)